CN101130111A - Biological absorbent artificial periosteum and method of producing the same - Google Patents
Biological absorbent artificial periosteum and method of producing the same Download PDFInfo
- Publication number
- CN101130111A CN101130111A CNA2007101519256A CN200710151925A CN101130111A CN 101130111 A CN101130111 A CN 101130111A CN A2007101519256 A CNA2007101519256 A CN A2007101519256A CN 200710151925 A CN200710151925 A CN 200710151925A CN 101130111 A CN101130111 A CN 101130111A
- Authority
- CN
- China
- Prior art keywords
- film
- artificial periosteum
- medicine
- fracture
- biological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 208000006735 Periostitis Diseases 0.000 title claims abstract description 31
- 210000003460 periosteum Anatomy 0.000 title claims abstract description 31
- 239000002250 absorbent Substances 0.000 title claims description 21
- 230000002745 absorbent Effects 0.000 title claims description 21
- 239000000463 material Substances 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 16
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 11
- 229920002521 macromolecule Polymers 0.000 claims description 16
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 10
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 229940053128 nerve growth factor Drugs 0.000 claims description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 9
- 230000011164 ossification Effects 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 229920001610 polycaprolactone Polymers 0.000 claims description 8
- 239000004632 polycaprolactone Substances 0.000 claims description 8
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 6
- 229950000845 politef Drugs 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229920001897 terpolymer Polymers 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 229960000448 lactic acid Drugs 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 238000009987 spinning Methods 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- -1 poly-hydroxy pentane ester Chemical class 0.000 claims description 3
- 230000009645 skeletal growth Effects 0.000 claims description 3
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 3
- IUPHTVOTTBREAV-UHFFFAOYSA-N 3-hydroxybutanoic acid;3-hydroxypentanoic acid Chemical compound CC(O)CC(O)=O.CCC(O)CC(O)=O IUPHTVOTTBREAV-UHFFFAOYSA-N 0.000 claims description 2
- 229920013642 Biopol™ Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920003232 aliphatic polyester Polymers 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 238000007731 hot pressing Methods 0.000 claims description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 239000003361 porogen Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229920005597 polymer membrane Polymers 0.000 claims 2
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 1
- 230000035876 healing Effects 0.000 abstract description 6
- 210000004872 soft tissue Anatomy 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000010392 Bone Fractures Diseases 0.000 description 26
- 206010017076 Fracture Diseases 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 4
- 238000007334 copolymerization reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002120 nanofilm Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a biologically absorbable artificial periosteum and making method through dispensing biologically degraded absorbable macromolecular film and the drug with function of improving fracture to heal with wt ratio at 10000: 0. 1-2: 1, wherein the artificial periosteum is film with porous structure, dense film with imperforate structure or compound structures film with part perforated or part unapertured, the macromolecular film degraded and absorbed by the living things is synthesized macromolecular film material or the natural macromolecular film material. The invention bonds the macromolecular film with the factors having improving bone to grow to avoid soft tissue embedding into the wreckage end during healing process effectively and improve blood circulation at the wreckage end to stimulate the sclerotomal cell activating, which achieves the purposes of improving the fracture to heal and reducing the healing time of the fracture as well.
Description
One, technical field
The present invention relates to medical biological absorbent artificial periosteum of a class and preparation method thereof.
Two, background technology
Fracture is the result of mechanicalness over loading, is the destruction of the seriality generation of bone.All fracture all can cause the complex injury of skeleton and surrounding soft tissue thereof.The healing of fracture is complicated process, and it is subjected to influence of various factors such as overall health of patients, local factor and degree of injury.In many influence factors, confession of the blood of fracture site and periosteum state are directly connected to the process of union of fracture.And factors such as the contact of fracture end, soft tissue embedding, also the healing important influence to fracturing.Orthopedist's common recognition is: in bone surgery, the fracture end periosteum stripping is partly more extensive, and the degree of the sclerotin at fracture site position and periosteum ischemia is just more serious; Embedding if any soft tissues such as muscle, tendon, fascias between the fracture site, will be to cause the most important reason of postoperative fracture disunion.In recent years, more and more many studies show that: the effect of the induced osteogenesis of bone formation generation albumen (BMP), promotion union of fracture can be clinical practice and brings positive impact.
At the complexity of orthopaedic disease itself, surgical doctor takes to alleviate fracture site tissue, muscle injury usually as far as possible, reduces scheme treatments such as periosteum stripping scope.But this can increase the difficulty of operation, the time of prolongation operation undoubtedly, and increases the risk of operation, and the probability of Post-operative complications and sequela is increased.Therefore how avoiding operation back " the embedded growth of fracture site soft tissue, prevent nonunion " is a great problem of present medical circle.
Three, summary of the invention
At the blank in the above-mentioned field, one of purpose of the present invention provides a kind of biological absorbent artificial periosteum.
Another purpose of the present invention provides a kind of preparation method of biological absorbent artificial periosteum.
These and other objects of the present invention will further embody and set forth by following detailed description and explanation.
Biological absorbent artificial periosteum of the present invention, be the perforated membrane with loose structure, the dense film of non-porous structure or the composite membrane of part meshed portion non-porous structure, be 100000 by biodegradable macromolecule member material that absorbs and the medicine with promotion union of fracture function with weight ratio: 0.1-2: 1 forms; Further, the weight ratio of the two is 10000: 1-2: 1; Further, the weight ratio of macromolecule member material and medicine is 1000: 1-1.5: 1, and what can select is that the weight ratio of molecular film material and medicine is 10: 1-1: 1.
In biological absorbent artificial periosteum of the present invention, the macromolecule member material that the biodegradable that is adopted absorbs can be synthetic high polymer, also can be natural polymer.Synthetic class Biodegradable high molecular be poly (l-lactic acid) (PLLA), poly-DL-lactic acid (PDLLA), copolymerization (L-lactic acid/DL-lactic acid) (PL-DL-LA), copolymerization (Acetic acid, hydroxy-, bimol. cyclic ester/lactide) (PLGA), polycaprolactone (PCL), poly-(Acetic acid, hydroxy-, bimol. cyclic ester/lactide/caprolactone) terpolymer (PGLC), polycaprolactone/polyethyleneglycol block copolymer (PCE), polycaprolactone/polyethyleneglycol/polylactide terpolymer (PCEL), and Biopol GO 4 (PHB), poly-hydroxy pentane ester (PHV) and the two aliphatic polyester family macromolecule or its blends such as copolymer.The natural biological degraded macromolecular is collagen, gelatin, chitosan and/or hyaluronic acid.
In biological absorbent artificial periosteum of the present invention, described medicine with promotion union of fracture function is one or more in exogenous skeletal growth factor bone formation generation albumen (BMP), basic fibroblast growth factor (bFGF), insulin like growth factor, nerve growth factor (NGF) and the platelet source multiplicaiton factor (PDGF).
The method for preparing biological absorbent artificial periosteum of the present invention comprises that solution-cast film build method, the hot-extrudable film build method of hot pressing, solution are injected into film method, porogen pore film build method, freeze-dried film build method, EFI and are spun into film method or are woven into one or more of film method.
In the method for preparing biological absorbent artificial periosteum of the present invention, described method specifically can adopt following steps: the macromolecule member material dissolution with solvents that elder generation absorbs biodegradable, add then and have the medicine that promotes the union of fracture function, back injection politef mould stirs, after treating the oxolane bone dry, desolventizing is 1～3 day under room temperature and vacuum condition, obtain the dense film that thickness is 0.1～0.4 millimeter non-porous structure, perhaps with macromolecular solution-30～--50 ℃ freezing down after desolventizing 1～3 day under vacuum condition again, obtain the perforated film that thickness is 0.1～0.4 millimeter loose structure.
Described method also can adopt following steps: the macromolecule member material dissolution with solvents that elder generation absorbs biodegradable, add then and have the medicine that promotes the union of fracture function, the back electric jet spinning spray webbing of employing that stirs becomes the nonwoven film, desolventizing 1～3 day under room temperature and vacuum condition obtains the perforated film that thickness is 0.1～0.4 millimeter loose structure again.
Above-mentioned solvent can be oxolane, dioxane, acetone, chloroform or dichloromethane, can be used alone, and also can use the mixture of arbitrary proportion.
The present invention adopts macromolecule membrane to combine with the somatomedin with promote osteogenesis, play the mechanical isolation effect that in fracture healing process, can prevent the soft tissue impaction fracture broken ends of fractured bone effectively, can promote fracture site position blood circulation, stimulating osteoblast to enliven again, thereby reach the purpose that promotes union of fracture, shortens healing time.
Biological absorbent artificial periosteum is a kind of good biocompatibility, the biodegradable and macromolecule membrane that absorbs.Utilize the barrier action of polymeric membrane, fracture face and surrounding tissue effectively can be isolated, prevent that the fibroblast in the surrounding tissue from invading fracture face, between fracture face and surrounding tissue, to form a physical barriers.The degradation rate of biological absorbent artificial periosteum of the present invention is determined according to the time parameter that postoperative body fibrin oozes out, owing to finally become water and carbon dioxide after the macromolecule degraded, therefore can be absorbed by the body or be excreted, finally can be fully disappear in the body and can be not residual in vivo.Because polymeric membrane has excellent biological compatibility, direct contact bone fracture, therefore can make somatomedin such as bone formation generation albumen or medicine directly surgical wound and on every side the position discharge, have the curative effect faster, higher, and dosage can significantly reduce than the systemic administration of routine.
Macromolecular material in the biological absorbent artificial periosteum had both played the buffer action of anti-surrounding tissue impaction fracture section of machinery, played pharmaceutical carrier again and to the controlled delivery of pharmaceutical agents release action; And the medicine in the film can play the effect that promotes osteoplastic effect, can play the stimulation bone resorption, therefore bone is rebuild to have dual regulation.
The formation of endochondral ossification and blood capillary is the important step of induced osteogenesis, but and the mesenchymal cell of exogenous skeletal growth factor BMP inducing peripheral tissue to be converted into the bone of irreversibility be cell, make that the position forms cartilage and osseous tissue beyond skeleton or skeleton; And basic fibroblast growth factor (bFGF) has the effect that stimulates chondrocyte proliferation, and is a kind of very strong capillary proliferation stimulant.
Biodegradable high molecular in the biological absorbent artificial periosteum of the present invention degradation time in vivo is 3-500 days, biological absorbent artificial periosteum promptly of the present invention will be in 3-500 days complete obiteration in the body.
The all raw material of Shi Yonging all is conventional uses in the present invention, can buy from market.
In the present invention, refer in particular to as non-, all amount, percentage ratios are unit of weight.
Below further specify the present invention by specific embodiment, but embodiment only be used for the explanation, can not limit the scope of the invention.
Four, the specific embodiment
Embodiment 1,
Copolymerization (Acetic acid, hydroxy-, bimol. cyclic ester/lactide) is (molecular weight 80,000) 10 parts (PLGA), with adding bone formation generation albumen (BMP) 0.001 part after 180 parts of dissolvings of oxolane, back injection politef mould stirs, after treating the oxolane bone dry, desolventizing is 48 hours under the room temperature vacuum condition, obtains thickness and be 0.1 millimeter atresia compact texture solid film.
Embodiment 2,
Press method and the step of embodiment 1, but adopt 0.01 part of 10 parts of collagens, 100 parts in water and insulin like growth factor (PDGF), the politef mould is injected in the back that stirs, and is freezing down at-40 ℃, vacuum and dehydration below-40 ℃ 48 hours, obtain thickness and be 0.3 millimeter perforated membrane then.
Embodiment 3,
Press method and the step of embodiment 1, but adopt 1 part of 10 parts of poly-(Acetic acid, hydroxy-, bimol. cyclic ester/lactide/caprolactone) terpolymers (PGLC) (molecular weight 50,000), 200 parts of dioxane and basic fibroblast growth factor (b-FGF), freezing down at-40 ℃, then vacuum and desolventizing below-40 ℃ 48 hours, obtain thickness and be 0.2 millimeter loose structure film.
Embodiment 4,
Press method and the step of embodiment 1, but adopt 0.001 part of 10 parts of hyaluronic acids, 190 parts in water and fibroblast growth factor (bFGF),-40 ℃ down freezing, then vacuum and desolventizing below-40 ℃ 48 hours, obtain thickness and be 0.2 millimeter loose structure film.
Embodiment 5,
Press method and the step of embodiment 1, but adopt (PL-DL-LA) (molecular weight 50,000) 10 parts of copolymerization (L-lactic acid/DL-lactic acid), with adding platelet source multiplicaiton factor (PDGF) 0.0001 part after 200 parts of dissolvings of acetone, back injection politef mould stirs, after treating the acetone bone dry, desolventizing is 48 hours under the room temperature vacuum condition, obtains thickness and be 0.1 millimeter atresia compact texture solid film.
Embodiment 6,
Press method and the step of embodiment 1, but adopt polycaprolactone/polyethyleneglycol/polylactide terpolymer (molecular weight 60,000) 10 parts, with adding bone formation generation albumen (BMP) 0.0005 part after 180 parts of dissolvings of dioxane, back injection politef mould stirs, in the room temperature vacuum drying oven, keep 48 hours after freeze-dried again to eliminate solvent fully, obtain thickness and be 0.15 millimeter perforated membrane.
Embodiment 7,
Press method and the step of embodiment 1, but adopt 10 parts of chitosans, add 0.001 part of nerve growth factor (NGF) after 125 parts of dissolvings of acetic acid weak solution, it is 0.10 millimeter porous nonwoven film that the electric jet spinning in back that stirs obtains thickness.
Embodiment 8,
Press method and the step of embodiment 7, the chitosan acetic acid weak solution electricity consumption jet spinning that will contain nerve growth factor (NGF) is sprayed onto part and is equipped with on the prepared atresia dense film of embodiment 1, obtains being the composite construction film of part meshed portion atresia.
Embodiment 9,
Press method and the step of embodiment 7, the hyaluronic acid solution electricity consumption jet spinning that will contain 0.01 part of 10 parts of hyaluronic acids, 35 parts of water/alcohol mixed solutions and nerve growth factor (NGF) is sprayed onto on the substrate, obtains the nonwoven film of loose structure.
Claims (10)
1. biological absorbent artificial periosteum, it is characterized in that macromolecule member material that is absorbed by biodegradable and the medicine with promotion union of fracture function are 100000 with weight ratio: 0.1-2: 1 forms, described artificial periosteum is the perforated film with loose structure, the dense film of non-porous structure or the composite construction film of part meshed portion non-porous structure, the macromolecule member material that described biodegradable absorbs is the synthetic high polymer membrane material, or is the natural polymer membrane material.
2. biological absorbent artificial periosteum according to claim 1, wherein the weight ratio of macromolecule member material and medicine is 10000: 1-2: 1.
3. biological absorbent artificial periosteum according to claim 1, wherein the weight ratio of macromolecule member material and medicine is 1000: 1-1.5: 1.
4. biological absorbent artificial periosteum according to claim 1, wherein the weight ratio of macromolecule member material and medicine is 10: 1-1: 1.
5. biological absorbent artificial periosteum according to claim 1, wherein the synthetic high polymer membrane material be following aliphatic polyester series high molecular one or more: terpolymer, polycaprolactone/polyethyleneglycol block copolymer, polycaprolactone/polyethyleneglycol/polylactide terpolymer and the Biopol GO 4 of poly (l-lactic acid), poly-DL-lactic acid, the L-lactic acid/copolymer of DL-lactic acid, the copolymer of Acetic acid, hydroxy-, bimol. cyclic ester/lactide, polycaprolactone, Acetic acid, hydroxy-, bimol. cyclic ester/lactide/caprolactone, poly-hydroxy pentane ester and the copolymer of the two; Natural biological degraded macromolecular membrane material is collagen, gelatin, chitosan and/or hyaluronic acid.
6. biological absorbent artificial periosteum according to claim 1, wherein said medicine with promotion union of fracture function are one or more in exogenous skeletal growth factor bone formation generation albumen (BMP), basic fibroblast growth factor (bFGF), insulin like growth factor, nerve growth factor (NGF) and the platelet source multiplicaiton factor (PDGF).
7. the preparation method of artificial periosteum according to claim 1, wherein said method comprise that solution-cast film build method, the hot-extrudable film build method of hot pressing, solution are injected into film method, porogen film build method, freeze-dried film build method, EFI and are spun into film method or are woven into one or more of film method.
8. the preparation method of artificial periosteum according to claim 7, adopt following steps: the macromolecule member material dissolution with solvents that elder generation absorbs biodegradable, add then and have the medicine that promotes the union of fracture function, back injection politef mould stirs, after treating the oxolane bone dry, desolventizing is 1～3 day under room temperature and vacuum condition, obtain thickness and be 0.1～0.4 millimeter non-porous structure dense film, perhaps with macromolecular solution-30～-50 ℃ down freezing after desolventizing 1～3 day under vacuum condition again, obtain thickness and be 0.1～0.4 millimeter loose structure perforated film.
9. according to the preparation method of claim 7 or 8 described artificial periosteums, adopt following steps: the macromolecule member material dissolution with solvents that elder generation absorbs biodegradable, add then and have the medicine that promotes the union of fracture function, the back electric jet spinning spray webbing of employing that stirs becomes the nonwoven film, desolventizing 1～3 day under room temperature and vacuum condition again obtains thickness and is 0.1～0.4 millimeter loose structure perforated film.
10. according to Claim 8 or 9 described methods, wherein said solvent is oxolane, dioxane, acetone, chloroform or dichloromethane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101519256A CN101130111A (en) | 2007-09-21 | 2007-09-21 | Biological absorbent artificial periosteum and method of producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101519256A CN101130111A (en) | 2007-09-21 | 2007-09-21 | Biological absorbent artificial periosteum and method of producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101130111A true CN101130111A (en) | 2008-02-27 |
Family
ID=39127615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101519256A Pending CN101130111A (en) | 2007-09-21 | 2007-09-21 | Biological absorbent artificial periosteum and method of producing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101130111A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102231992A (en) * | 2008-09-09 | 2011-11-02 | 生物模拟治疗公司 | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
| CN102648987A (en) * | 2012-04-26 | 2012-08-29 | 暨南大学 | Asymmetric double-crosslinked composite material, as well as preparation method and application of same |
| CN102949750A (en) * | 2012-11-15 | 2013-03-06 | 中国人民解放军第三军医大学 | Double-layer electrospinning bionic periosteum and method for preparing same |
| CN104414772A (en) * | 2013-09-06 | 2015-03-18 | 山东百多安医疗器械有限公司 | In-vivo degradable and absorbable artificial medical tissue repairing film |
| CN107519528A (en) * | 2017-08-30 | 2017-12-29 | 山东省立医院 | A kind of bone wax of biological absorbable and preparation method thereof |
| CN107683302A (en) * | 2015-06-02 | 2018-02-09 | 伊西康公司 | Based on the absorbable medical treatment device of new membrane and foam made of showing the lactide of Long-term absorption characteristic and the hypocrystalline segmentation copolymer of ε caprolactones |
| CN108066325A (en) * | 2017-08-22 | 2018-05-25 | 牛云飞 | The sustained release Indomethacin Absorbable membrane and preparation method of prevention of postoperative ectopic ossification and application |
-
2007
- 2007-09-21 CN CNA2007101519256A patent/CN101130111A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102231992A (en) * | 2008-09-09 | 2011-11-02 | 生物模拟治疗公司 | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
| CN102231992B (en) * | 2008-09-09 | 2015-05-20 | 生物模拟治疗公司 | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
| CN102648987A (en) * | 2012-04-26 | 2012-08-29 | 暨南大学 | Asymmetric double-crosslinked composite material, as well as preparation method and application of same |
| CN102648987B (en) * | 2012-04-26 | 2014-06-25 | 暨南大学 | Asymmetric double-crosslinked composite material, as well as preparation method and application of same |
| CN102949750A (en) * | 2012-11-15 | 2013-03-06 | 中国人民解放军第三军医大学 | Double-layer electrospinning bionic periosteum and method for preparing same |
| CN102949750B (en) * | 2012-11-15 | 2014-11-05 | 中国人民解放军第三军医大学 | Double-layer electrospinning bionic periosteum and method for preparing same |
| CN104414772A (en) * | 2013-09-06 | 2015-03-18 | 山东百多安医疗器械有限公司 | In-vivo degradable and absorbable artificial medical tissue repairing film |
| CN107683302A (en) * | 2015-06-02 | 2018-02-09 | 伊西康公司 | Based on the absorbable medical treatment device of new membrane and foam made of showing the lactide of Long-term absorption characteristic and the hypocrystalline segmentation copolymer of ε caprolactones |
| CN108066325A (en) * | 2017-08-22 | 2018-05-25 | 牛云飞 | The sustained release Indomethacin Absorbable membrane and preparation method of prevention of postoperative ectopic ossification and application |
| CN108066325B (en) * | 2017-08-22 | 2022-11-22 | 中国人民解放军海军军医大学第一附属医院 | Sustained-release indomethacin absorbable film for preventing postoperative heterotopic ossification and its preparation method and application |
| CN107519528A (en) * | 2017-08-30 | 2017-12-29 | 山东省立医院 | A kind of bone wax of biological absorbable and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davachi et al. | Polylactic acid in medicine | |
| RU2491961C2 (en) | Artificial dura mater and method of its production | |
| Nair et al. | Biodegradable polymers as biomaterials | |
| CN101130111A (en) | Biological absorbent artificial periosteum and method of producing the same | |
| WO2001012240A1 (en) | Biological materials | |
| CN104474589A (en) | Guided tissue regeneration membrane as well as preparation method and application thereof | |
| JP2008509752A (en) | Surgical prosthesis with biodegradable and non-biodegradable regions | |
| CN107737367A (en) | The vertebrae minimally-invasive of the bone cement combined using calcium phosphate is treated | |
| CN104414772A (en) | In-vivo degradable and absorbable artificial medical tissue repairing film | |
| WO2018025186A1 (en) | Nerve guidance conduits, methods of production and uses thereof | |
| CN103483625A (en) | Absorbable and degradable multipurpose biocompatible material | |
| Liu et al. | Applications of bacterial cellulose-based composite materials in hard tissue regenerative medicine | |
| Dean et al. | Effect of transforming growth factor β2 on marrow-infused foam poly (propylene fumarate) tissue-engineered constructs for the repair of critical-size cranial defects in rabbits | |
| Biswal | Recent progress in PLA‐based composite and their application to biomedical and cosmetic fields | |
| JP3860417B2 (en) | Transplant prosthesis with long-term stability | |
| KR100464930B1 (en) | Barrier membrance for guided tissue regeneration and the preparation thereof | |
| CN1403167A (en) | Hard tissue repairing material and its prepn | |
| CN111973797B (en) | Non-invasive implantation high-viscosity adhesive material for orthopedics department and preparation method and application thereof | |
| CN109907979A (en) | Intradermal needling and preparation method thereof | |
| Mills | The role of polymer additives in enhancing the response of calcium phosphate cement | |
| CN116392639B (en) | Full-layer repair double-layer bracket and preparation method and application thereof | |
| CN100381181C (en) | Step-by-step degradation of bioactive implant materials containing growth-promoting factors | |
| KR20190012958A (en) | Medicinal suture yarn coated with polydeoxyribonucleotide and method of manufacturing the same | |
| CN115501396B (en) | Degradable tissue scaffold and preparation method and application thereof | |
| Teimouri et al. | Protein-Based Hybrid Scaffolds: Application in Bone Tissue Engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080227 |